← 返回前沿论文

剂量密集剂量强化新辅助化疗治疗的三阴性乳腺癌患者中治疗后基质 TIL(肿瘤浸润淋巴细胞)与生存的负相关关系

英文原题:Negative Relationship between Post-Treatment Stromal Tumor-Infiltrating Lymphocyte (TIL) and Survival in Triple-Negative Breast Cancer Patients Treated with Dose-Dense Dose-Intense NeoAdjuvant Chemotherapy.

PubMed 2022/03/04(内容时间) Cancers (Basel) Q2 · IF 4.8(JCR 2025)

研究概要

我们的结果表明,NAC后TIL富集的TNBC患者复发风险更高。

中文摘要

背景:三阴性乳腺癌(TNBC)患者除非在新辅助化疗(NAC)后达到病理完全缓解(pCR),否则预后较差。很少有研究分析剂量密集剂量增强(dd-di)NAC后TIL水平的变化。患者与方法:2009年至2018年,117例TNBC患者在我们机构接受了dd-di NAC。我们旨在确定与NAC前和NAC后TIL水平相关的因素,以及肿瘤学结局无复发生存期(RFS)和总生存期(OS)。结果:NAC前和NAC后TIL水平的中位数分别为15%和3%。治疗引起的TIL水平变化与代谢反应(SUV)和pCR显著相关。高NAC后TIL水平与两周期NAC后代谢反应较弱、NAC完成时存在残留病灶和淋巴结受累相关。在多变量分析中,高NAC后TIL水平独立预测较差的RFS和较差的OS(每增加10%的HR = 1.4,95%CI(1.1;1.9)p = 0.014,以及每增加10%的HR = 1.8,95%CI(1.3 2.3),p < 0.0001)。结论:我们的结果表明,NAC后TIL富集的TNBC患者复发风险更高。这些患者是临床试验中辅助治疗(如免疫治疗)的潜在候选者。

展开英文摘要原文

Background: Patients with triple-negative breast cancers (TNBC) have a poor prognosis unless a pathological complete response (pCR) is achieved after neoadjuvant chemotherapy (NAC). Few studies have analyzed changes in TIL levels following dose-dense dose-intense (dd-di) NAC. Patients and methods: From 2009 to 2018, 117 patients with TNBC received dd-di NAC at our institution. We aimed to identify factors associated with pre- and post-NAC TIL levels, and oncological outcomes relapse-free survival (RFS), and overall survival (OS). Results: Median pre-NAC and post-NAC TIL levels were 15% and 3%, respectively. Change in TIL levels with treatment was significantly correlated with metabolic response (SUV) and pCR. High post-NAC TIL levels were associated with a weak metabolic response after two cycles of NAC, with the presence of residual disease and nodal involvement at NAC completion. In multivariate analyses, high post-NAC TIL levels independently predicted poor RFS and poor OS (HR = 1.4 per 10% increment, 95%CI (1.1; 1.9) p = 0.014 and HR = 1.8 per 10% increment 95%CI (1.3 2.3), p < 0.0001, respectively). Conclusion: Our results suggest that TNBC patients with TIL enrichment after NAC are at higher risk of relapse. These patients are potential candidates for adjuvant treatment, such as immunotherapy, in clinical trials.

论文信息

作者
Giacchetti S、Faucheux L、Gardair C、Cuvier C、de Roquancourt A、Campedel L、Groheux D、de Bazelaire C
第一作者单位
Breast Disease Unit (S&#xe9;nopole), AP-HP, H&#xf4;pital Saint-Louis, F-75010 Paris, France.France
通讯作者单位
Residual Tumor &amp; Response to Treatment Laboratory, RT2Lab, INSERM, U932 Immunity and Cancer, Institut Curie, 26 rue d'Ulm, University Paris, F-75005 Paris, France.France
期刊
Cancers2022 Mar 4
原文标识
PubMed 35267639 · DOI 10.3390/cancers14051331